论文标题
潮汐:拓扑提取的药物成瘾学习
TIDAL: Topology-Inferred Drug Addiction Learning
论文作者
论文摘要
药物成瘾或药物过量是全球公共卫生危机,由于复杂的机制,抗死药物的设计仍然是一个重大挑战。由于实验性药物筛查和优化太耗时且昂贵,因此迫切需要开发创新的人工智能(AI)方法来应对挑战。我们通过拓扑提取的药物成瘾学习(TIDAL)来应对这一挑战,该挑战是由整合拓扑拉普拉斯,深度双向变压器和合奏辅助神经网络(EANNS)构建的。拓扑Laplacian是一种新型的代数拓扑工具,将分子拓扑不变性和代数不变性嵌入其谐波光谱和非谐波光谱中。这些不变的补体从双向变压器提取的序列信息。我们验证了与22种药物成瘾,4个HERG和12个DAT数据集的拟议潮汐框架,这表明潮汐是对药物成瘾数据建模和分析的最新框架。我们对当前的药物成瘾候选者进行跨目标分析,以提醒其副作用并确定其重新利用潜力,从而揭示了药物介导的线性和双线性目标相关性。最后,将潮汐应用于相对疗效,重新利用潜力以及12种现有抗添加药物的潜在副作用。我们的结果表明,Tidal为紧迫的反替代成瘾药物开发提供了一种新的计算策略。
Drug addiction or drug overdose is a global public health crisis, and the design of anti-addiction drugs remains a major challenge due to intricate mechanisms. Since experimental drug screening and optimization are too time-consuming and expensive, there is urgent need to develop innovative artificial intelligence (AI) methods for addressing the challenge. We tackle this challenge by topology-inferred drug addiction learning (TIDAL) built from integrating topological Laplacian, deep bidirectional transformer, and ensemble-assisted neural networks (EANNs). The topological Laplacian is a novel algebraic topology tool that embeds molecular topological invariants and algebraic invariants into its harmonic spectra and non-harmonic spectra, respectively. These invariants complement sequence information extracted from a bidirectional transformer. We validate the proposed TIDAL framework on 22 drug addiction related, 4 hERG, and 12 DAT datasets, showing that TIDAL is a state-of-the-art framework for the modeling and analysis of drug addiction data. We carry out cross-target analysis of the current drug addiction candidates to alert their side effects and identify their repurposing potentials, revealing drugmediated linear and bilinear target correlations. Finally, TIDAL is applied to shed light on relative efficacy, repurposing potential, and potential side effects of 12 existing anti-addiction medications. Our results suggest that TIDAL provides a new computational strategy for pressingly-needed anti-substance addiction drug development.